Cargando…

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG

(131)I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) (131)I-MIBG in a patient with metastatic paraganglioma. Ten courses of (131)I-MIBG therapy were g...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezziddin, Samer, Sabet, Amir, Ko, Yon-Dschun, Xun, Sunny, Matthies, Alexander, Biersack, Hans-Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277473/
https://www.ncbi.nlm.nih.gov/pubmed/22277577
http://dx.doi.org/10.1186/1748-717X-7-8
_version_ 1782223495752581120
author Ezziddin, Samer
Sabet, Amir
Ko, Yon-Dschun
Xun, Sunny
Matthies, Alexander
Biersack, Hans-Jürgen
author_facet Ezziddin, Samer
Sabet, Amir
Ko, Yon-Dschun
Xun, Sunny
Matthies, Alexander
Biersack, Hans-Jürgen
author_sort Ezziddin, Samer
collection PubMed
description (131)I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) (131)I-MIBG in a patient with metastatic paraganglioma. Ten courses of (131)I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually the patient died of progression. The observed cumulative activity of (131)I-MIBG represents the highest value reported to our knowledge, and even though 12.6 GBq of (90)Y-DOTATOC were added intermediately, no associated relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment.
format Online
Article
Text
id pubmed-3277473
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32774732012-02-11 Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG Ezziddin, Samer Sabet, Amir Ko, Yon-Dschun Xun, Sunny Matthies, Alexander Biersack, Hans-Jürgen Radiat Oncol Case Report (131)I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) (131)I-MIBG in a patient with metastatic paraganglioma. Ten courses of (131)I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually the patient died of progression. The observed cumulative activity of (131)I-MIBG represents the highest value reported to our knowledge, and even though 12.6 GBq of (90)Y-DOTATOC were added intermediately, no associated relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment. BioMed Central 2012-01-25 /pmc/articles/PMC3277473/ /pubmed/22277577 http://dx.doi.org/10.1186/1748-717X-7-8 Text en Copyright ©2012 Ezziddin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ezziddin, Samer
Sabet, Amir
Ko, Yon-Dschun
Xun, Sunny
Matthies, Alexander
Biersack, Hans-Jürgen
Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
title Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
title_full Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
title_fullStr Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
title_full_unstemmed Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
title_short Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
title_sort repeated radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)i-mibg
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277473/
https://www.ncbi.nlm.nih.gov/pubmed/22277577
http://dx.doi.org/10.1186/1748-717X-7-8
work_keys_str_mv AT ezziddinsamer repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg
AT sabetamir repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg
AT koyondschun repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg
AT xunsunny repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg
AT matthiesalexander repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg
AT biersackhansjurgen repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg